Isomorphic Labs Appoints Ben Wolf as Chief Medical Officer, Expands to U.S. Hub in Cambridge
Isomorphic Labs has appointed Dr. Ben B. Wolf as Chief Medical Officer and opened a new U.S. office in Cambridge, Massachusetts, marking a strategic expansion following its $600M raise as the DeepMind spinout strengthens clinical leadership and infrastructure to advance its AI-based drug discovery platform toward the clinic.
Dr. Wolf brings nearly two decades of clinical development experience, including leadership roles at Relay Therapeutics and KSQ Therapeutics, where he led oncology programs based on precision medicine and CRISPR technologies. Earlier in his career, he helped register kinase inhibitors Ayvakit and Gavreto at Blueprint Medicines.
Dr. Ben Wolf
He will oversee clinical translation efforts for Isomorphic's AI-designed compounds, joining the company as it scales its drug development infrastructure following its $600 million external raise earlier this year.
The new U.S. site in Kendall Square will serve as an operational hub alongside existing locations in London and Lausanne, integrating biomedical talent with the company’s foundational AI modeling expertise.
Isomorphic Labs was founded in 2021 by DeepMind CEO Demis Hassabis and builds on the AlphaFold platform. In May 2024, the company co-released AlphaFold 3 with DeepMind, a model capable of predicting biomolecular structures and interactions across diverse modalities. Isomorphic continues to build its unified drug design engine to generate therapeutics across multiple disease areas.
"We're entering a new era for drug discovery in which our next-generation AI drug design engine can unlock deeper scientific insights," said Sir Demis Hassabis, CEO of Isomorphic Labs. "To turn those insights into real breakthroughs we need to translate them into medicines that can transform patient lives. Ben's expertise in advancing clinical programs from early development through registration makes him the ideal person to lead our work in this area. I’m delighted to have him on board!"
Topics: Startups & Deals
